Literature DB >> 1726928

The molecular biology of the human anaplastic thyroid carcinoma cell.

N E Heldin1, B Westermark.   

Abstract

In the present investigation we show data from our studies of anaplastic human thyroid carcinoma cell lines. The cell lines employed in the study were HTh 7, HTh 74, C 643 and SW 1736, all derived from tumours diagnosed as anaplastic thyroid carcinomas. Northern blot analysis with four different thyroid specific cDNA probes showed a varying pattern of expression. Thyroglobulin mRNA was found in three of the carcinoma cell lines, although the signal was very weak compared to the expression in tissue from a toxic goitre, used as positive control. Interestingly, two of the cell lines expressed the receptor for thyrotropin, but none of them contained thyroperoxidase mRNA. Three of the cell lines expressed mRNA for receptors platelet-derived growth factor, PDGFR-alpha and/or PDGFR-beta type. Messenger RNA of a thyroid specific transcription factor, TTF-1, known to regulate the normal function of thyrocytes, was found in the toxic goitre but not in the anaplastic thyroid carcinoma cell lines. Lack of expression of TTF-1 might the immediate cause of the anaplastic phenotype, considering the possibility that TTF-1 functions as a master regulatory gene in thyroid cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726928

Source DB:  PubMed          Journal:  Thyroidology        ISSN: 1121-7596


  10 in total

1.  Nuclear cysteine cathepsin variants in thyroid carcinoma cells.

Authors:  Sofia Tedelind; Kseniia Poliakova; Amanda Valeta; Ruth Hunegnaw; Eyoel Lemma Yemanaberhan; Nils-Erik Heldin; Junichi Kurebayashi; Ekkehard Weber; Nataša Kopitar-Jerala; Boris Turk; Matthew Bogyo; Klaudia Brix
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

2.  Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.

Authors:  Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Ulrike Hinterseher; Detlef K Bartsch; Sebastian Hoffmann
Journal:  Endocrine       Date:  2012-04-05       Impact factor: 3.633

3.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

4.  Expression of hedgehog signalling pathway in anaplastic thyroid cancer.

Authors:  Ulrike Hinterseher; Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Detlef K Bartsch; Stefan Hauptmann; Brandon H Greene; Volker Fendrich; Sebastian Hoffmann
Journal:  Endocrine       Date:  2013-07-17       Impact factor: 3.633

5.  Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.

Authors:  S Hoffmann; S Gläser; A Wunderlich; S Lingelbach; C Dietrich; A Burchert; H Müller; M Rothmund; A Zielke
Journal:  Langenbecks Arch Surg       Date:  2006-10-12       Impact factor: 3.445

6.  Cathepsin B trafficking in thyroid carcinoma cells.

Authors:  Sofia Tedelind; Silvia Jordans; Henrike Resemann; Galia Blum; Matthew Bogyo; Dagmar Führer; Klaudia Brix
Journal:  Thyroid Res       Date:  2011-08-03

7.  Increased expression of CD44 variants in differentiated thyroid cancers.

Authors:  T Takano; H Sumizaki; K Nakano; F Matsuzuka; K Kuma; N Amino
Journal:  Jpn J Cancer Res       Date:  1996-12

8.  Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death.

Authors:  Sabine Wächter; Alexander I Damanakis; Moritz Elxnat; Silvia Roth; Annette Wunderlich; Frederik A Verburg; Sebastian A Fellinger; Detlef K Bartsch; Pietro Di Fazio
Journal:  J Clin Med       Date:  2018-03-21       Impact factor: 4.241

9.  An epistatic interaction between the PAX8 and STK17B genes in papillary thyroid cancer susceptibility.

Authors:  Iñigo Landa; Cesar Boullosa; Lucía Inglada-Pérez; Ana Sastre-Perona; Susana Pastor; Antonia Velázquez; Veronika Mancikova; Sergio Ruiz-Llorente; Francesca Schiavi; Ricard Marcos; Nuria Malats; Giuseppe Opocher; Ramon Diaz-Uriarte; Pilar Santisteban; Alfonso Valencia; Mercedes Robledo
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

10.  Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.

Authors:  Sabine Wächter; Annette Wunderlich; Brandon H Greene; Silvia Roth; Moritz Elxnat; Sebastian A Fellinger; Frederik A Verburg; Markus Luster; Detlef K Bartsch; Pietro Di Fazio
Journal:  Int J Mol Sci       Date:  2018-07-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.